Journals / Bakırköy Tıp Dergisi / 2021 / Cilt: 17 - Sayı: 4

Evaluation of S100B Protein in Patients with Schizophrenia with Seropositive and Seronegative Toxoplasma

Toxoplasma Seropozitif ve Seronegatif Şizofreni Hastalarında S100B Proteininin Değerlendirilmesi

Pages
420–424
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Some studies report a role for S100B in schizophrenia; however, uncertainties still exist and are in some ways contradictory.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: S100B is a calcium-binding protein that is secreted from astrocytes and other glial cells in the central nervous system and may affect the growth and/or differentiation of neurons and astrocytes.
📊
Key Findings & Data:This study aimed to evaluate S100B protein levels in patients with schizophrenia having seropositive and seronegative toxoplasma.
💡
Conclusion & Impact:Some studies report a role for S100B in schizophrenia; however, uncertainties still exist and are in some ways contradictory.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: S100B is a calcium-binding protein that is secreted from astrocytes and other glial cells in the central nervous system and may affect the growth and/or differentiation of neurons and astrocytes. The neuropathological studies in cell cultures of Toxoplasma gondii and postmortem studies in patients with schizophrenia revealed many glial abnormalities, particularly in astrocytes. This study aimed to evaluate S100B protein levels in patients with schizophrenia having seropositive and seronegative toxoplasma. Methods: This study included 40 patients with schizophrenia and 39 healthy control groups, with 20 toxoplasma seropositive in each group. The patients’ psychopathology were evaluated with the positive and negative syndrome scale (PANSS). S100B level and T. gondii immunoglobulin G (IgG) were analyzed by electrochemiluminescence immunoassay and the enzyme-linked immune-sorbent assay method, respectively. Results: No significant difference was found in S100B values between the patients with schizophrenia and healthy controls (p=0.94). No statistically significant correlations were found between S100B and both PANSS subscale scores and disease duration. S100B median values between toxoplasma IgG-positive and negative groups have no statistically significant difference in both healthy controls (p=0.38) and patients with schizophrenia (p=0.93). Conclusion: This study found no association between S100B protein levels and both schizophrenia and latent toxoplasma. Some studies report a role for S100B in schizophrenia; however, uncertainties still exist and are in some ways contradictory.

Özet

Amaç: S100B, merkezi sinir sistemindeki astrositlerden ve diğer glial hücrelerden salgılanan, nöronların ve astrositlerin büyümesinde ve/veya farklılaşmasında rol oynayabilen kalsiyum bağlayıcı bir proteindir. Toxoplasma gondii hücre kültürlerinde yapılan nöropatolojik çalışmalarda ve şizofreni hastalarında yapılan postmortem çalışmalarda, özellikle astrositlerde olmak üzere birçok glial anormallik gösterilmiştir. Bu çalışmanın amacı, toksoplazma seronegatif ve seropozitif şizofreni hastalarında S100B protein düzeylerini değerlendirmekti. Gereç ve Yöntem: Çalışmaya her grupta 20 toksoplazma seropozitif olmak üzere toplam 40 şizofreni hastası ve 39 sağlıklı kontrol grubu dahil edildi. Hastaların psikopatolojisi, pozitif ve negatif sendrom ölçeği (PANSS) ile değerlendirildi. S100B seviyesi ve T. gondii immünoglobulin (IgG), sırasıyla elektrokemilüminesans immünoassay yöntemi ve enzime bağlı immün-sorbent yöntemi ile analiz edildi. Bulgular: Şizofreni hastaları ile sağlıklı kontroller arasında S100B değerlerinde anlamlı fark yoktu (p=0,94). S100B ile hem PANSS skorları hem de hastalık süresi arasında istatistiksel olarak anlamlı bir ilişki yoktu. Toxoplasma immünoglobulin G (IgG) pozitif ve negatif gruplar arasında S100B medyan değerlerinde hem sağlıklı kontrollerde (p=0,38) hem de şizofreni hastalarında (p=0.93) istatistiksel olarak anlamlı bir fark yoktu. Sonuç: Bu çalışmada, S100B protein seviyeleri ile hem şizofreni hem de latent toksoplazma arasında bir ilişki bulunmamıştır. Bazı çalışmalar S100B’nin şizofrenide bir rolü olduğunu bildirmektedir, ancak bu konuda belirsizlikler hala mevcuttur ve bazı yönlerden çelişkilidir

🔖

Cite This Article

Karabulut, N., Namlı, M. N., Ayyıldız, H. (2022). Evaluation of S100B Protein in Patients with Schizophrenia with Seropositive and Seronegative Toxoplasma. Bakırköy Tıp Dergisi, Cilt: 17 - Sayı: 4, 420–424. https://ajindex.com/articles/459955

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Chaudhury A, Ramana BV. Schizophrenia and bipolar disorders: The Toxoplasma connection. Trop Parasitol 2019;9:71-6
  2. Xiao J, Prandovszky E, Kannan G, Pletnikov MV, Dickerson F, Severance EG, et al. Toxoplasma gondii: Biological Parameters of the Connection to Schizophrenia. Schizophr Bull 2018;44:983-92
  3. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965;19:739-44
  4. Kozłowska E, Brzezińska-Błaszczyk E, Agier J, Wysokiński A, Żelechowska P. Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia. J Psychiatr Res 2021;138:380-7
  5. Michetti F, D’Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem 2019;148:168-87
  6. Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003;21:97-108
  7. Aleksovska K, Leoncini E, Bonassi S, Cesario A, Boccia S, Frustaci A. Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia. PLoS One 2014;9:e106342
  8. Qi LY, Xiu MH, Chen DC, Wang F, Kosten TA, Kosten TR, et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009;462:113-7
  9. Yelmo-Cruz S, Morera-Fumero AL, Abreu-González P. S100B and schizophrenia. Psychiatry Clin Neurosci 2013;67:67-75
  10. Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H, et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008;42:868-76
  11. Steiner J, Schmitt A, Schroeter ML, Bogerts B, Falkai P, Turck CW, et al. S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. Eur Arch Psychiatry Clin Neurosci 2014;264:311-6
  12. Katsel P, Byne W, Roussos P, Tan W, Siever L, Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology 2011;36:1171-7
  13. Deng H, Kahlon RS, Mohite S, Amin PA, Zunta-Soares G, Colpo GD, et al. Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia. Psychiatr Q 2018;89:53-60
  14. Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Gonçalves CA, Fonseca M, et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2